Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice

Current antibody-drug conjugates (ADCs) target internalising receptors on cancer cells. Here, the authors report the development and in vivo validation of a non-internalising ADC with the capacity to target cancer cells and release its therapeutic cargo extracellularly via a chemical trigger.

Bibliographic Details
Main Authors:	Raffaella Rossin, Ron M. Versteegen, Jeremy Wu, Alisher Khasanov, Hans J. Wessels, Erik J. Steenbergen, Wolter ten Hoeve, Henk M. Janssen, Arthur H. A. M. van Onzen, Peter J. Hudson, Marc S. Robillard
Format:	Article
Language:	English
Published:	Nature Publishing Group 2018-05-01
Series:	Nature Communications
Online Access:	https://doi.org/10.1038/s41467-018-03880-y

id	doaj-b6e9e26c80024b1e84795b448f5f9b65
record_format	Article
spelling	doaj-b6e9e26c80024b1e84795b448f5f9b652021-05-11T10:07:42ZengNature Publishing GroupNature Communications2041-17232018-05-019111110.1038/s41467-018-03880-yChemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in miceRaffaella Rossin0Ron M. Versteegen1Jeremy Wu2Alisher Khasanov3Hans J. Wessels4Erik J. Steenbergen5Wolter ten Hoeve6Henk M. Janssen7Arthur H. A. M. van Onzen8Peter J. Hudson9Marc S. Robillard10Tagworks PharmaceuticalsSyMO-Chem B.V.Avipep Pty LtdLevena Biopharma, 4955 Directors PlaceRadboud Proteomics Centre, Department of Laboratory Medicine, Radboud University Medical CenterDepartment of Pathology, Radboud University Medical CenterSyncom B.V.SyMO-Chem B.V.Tagworks PharmaceuticalsAvipep Pty LtdTagworks PharmaceuticalsCurrent antibody-drug conjugates (ADCs) target internalising receptors on cancer cells. Here, the authors report the development and in vivo validation of a non-internalising ADC with the capacity to target cancer cells and release its therapeutic cargo extracellularly via a chemical trigger.https://doi.org/10.1038/s41467-018-03880-y
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Raffaella Rossin Ron M. Versteegen Jeremy Wu Alisher Khasanov Hans J. Wessels Erik J. Steenbergen Wolter ten Hoeve Henk M. Janssen Arthur H. A. M. van Onzen Peter J. Hudson Marc S. Robillard
spellingShingle	Raffaella Rossin Ron M. Versteegen Jeremy Wu Alisher Khasanov Hans J. Wessels Erik J. Steenbergen Wolter ten Hoeve Henk M. Janssen Arthur H. A. M. van Onzen Peter J. Hudson Marc S. Robillard Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice Nature Communications
author_facet	Raffaella Rossin Ron M. Versteegen Jeremy Wu Alisher Khasanov Hans J. Wessels Erik J. Steenbergen Wolter ten Hoeve Henk M. Janssen Arthur H. A. M. van Onzen Peter J. Hudson Marc S. Robillard
author_sort	Raffaella Rossin
title	Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
title_short	Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
title_full	Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
title_fullStr	Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
title_full_unstemmed	Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
title_sort	chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice
publisher	Nature Publishing Group
series	Nature Communications
issn	2041-1723
publishDate	2018-05-01
description	Current antibody-drug conjugates (ADCs) target internalising receptors on cancer cells. Here, the authors report the development and in vivo validation of a non-internalising ADC with the capacity to target cancer cells and release its therapeutic cargo extracellularly via a chemical trigger.
url	https://doi.org/10.1038/s41467-018-03880-y
work_keys_str_mv	AT raffaellarossin chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT ronmversteegen chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT jeremywu chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT alisherkhasanov chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT hansjwessels chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT erikjsteenbergen chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT woltertenhoeve chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT henkmjanssen chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT arthurhamvanonzen chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT peterjhudson chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice AT marcsrobillard chemicallytriggereddrugreleasefromanantibodydrugconjugateleadstopotentantitumouractivityinmice
_version_	1721448646585614336

Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice

Similar Items